Search by Drug Name or NDC
NDC 00071-0237-24 Zarontin 250 mg/1 Details
Zarontin 250 mg/1
Zarontin is a ORAL CAPSULE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Parke-Davis Div of Pfizer Inc. The primary component is ETHOSUXIMIDE.
MedlinePlus Drug Summary
Ethosuximide is used to control absence seizures (petit mal) (a type of seizure in which there is a very short loss of awareness during which the person may stare straight ahead or blink his eyes and does not respond to others). Ethosuximide is in a class of medications called anticonvulsants. It works by reducing abnormal electrical activity in the brain.
Related Packages: 00071-0237-24Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Ethosuximide
Product Information
| NDC | 00071-0237 |
|---|---|
| Product ID | 0071-0237_edbd0e03-32f6-4f34-9686-f63912bbe623 |
| Associated GPIs | 72400010000105 |
| GCN Sequence Number | 004554 |
| GCN Sequence Number Description | ethosuximide CAPSULE 250 MG ORAL |
| HIC3 | H4B |
| HIC3 Description | ANTICONVULSANTS |
| GCN | 17420 |
| HICL Sequence Number | 001891 |
| HICL Sequence Number Description | ETHOSUXIMIDE |
| Brand/Generic | Brand |
| Proprietary Name | Zarontin |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Ethosuximide |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | CAPSULE |
| Route | ORAL |
| Active Ingredient Strength | 250 |
| Active Ingredient Units | mg/1 |
| Substance Name | ETHOSUXIMIDE |
| Labeler Name | Parke-Davis Div of Pfizer Inc |
| Pharmaceutical Class | Anti-epileptic Agent [EPC], Decreased Central Nervous System Disorganized Electrical Activity [PE] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA012380 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00071-0237-24 (00071023724)
| NDC Package Code | 0071-0237-24 |
|---|---|
| Billing NDC | 00071023724 |
| Package | 100 CAPSULE in 1 BOTTLE (0071-0237-24) |
| Marketing Start Date | 2000-09-22 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |